Stevanato Group SpA reports results for the quarter ended June 30 - Earnings Summary
Stevanato Group SpA reports results for the quarter ended June 30 - Earnings Summary
Stevanato Group SpA STVN.N reported quarterly adjusted earnings of 14 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 11 cents. The mean expectation of ten analysts for the quarter was for earnings of 13 cents per share. Wall Street expected results to range from 12 cents to 14 cents per share.
Revenue rose 7.9% to €302.00 million from a year ago; analysts expected €298.40 million.
Stevanato Group SpA's reported EPS for the quarter was 8 cents.
The company reported quarterly net income of €23 million.
Stevanato Group SpA shares had risen by 13.9% this quarter and gained 2.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Stevanato Group SpA is $26.00, about 20.8% above its last closing price of $20.59
This summary was machine generated from LSEG data August 4 at 11:31 a.m. UTC. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 0.13 | 0.14 | Beat |
Mar. 31 2026 | 0.10 | 0.11 | Beat |
Dec. 31 2025 | 0.17 | 0.18 | Beat |
Sep. 30 2025 | 0.12 | 0.14 | Beat |
Recent news on Stevanato SpA
See all newsStevanato Group SpA reports results for the quarter ended June 30 - Earnings Summary
Corrected: BRIEF-Stevanato Q2 Net Income EUR 23 Million
SCHOTT Pharma jumps as DB ups to 'buy' on growth prospects
Italy's Stevanato Q1 revenue rises more than expected, helped by GLP-1 demand
Italy's Stevanato Q4 revenue beats on BDS unit strength